
P R E S S R E L E A S E

Ypsomed now supplies the YpsoPen® in Poland

Burgdorf, 30 June 2015, 07:00 – Ypsomed now supplies the Polish company Polfa Tarchomin S. A. with its reusable and affordable YpsoPen®. The YpsoPen® is being introduced to the Polish market and will be used to administer Polfa Tarchomin's insulin. Negotiations are in place to expand cooperation to other countries.

The PolhuminPen, an injection system based on the YpsoPen® platform, was introduced to Europe for the first time at the beginning of June in 2015. Polfa Tarchomin markets the reusable insulin pen together with its insulin Polhumin®. The Polish pharmaceutical company based in Warsaw is one of the oldest pharmaceutical companies in the world. Ypsomed, for its part, is very pleased that Polfa Tarchomin has once again chosen an injection system from the Burgdorf diabetes specialist.

For further information, please contact Benjamin Overney, Head of Investor & Public Relations at Ypsomed Holding AG, by phone at +41 34 424 41 59 or by email (benjamin.overney@ypsomed.com).

About the Ypsomed Group

The Ypsomed Group is the leading developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with 30 years of experience. Founded in 2003 from the well-known company Disetronic Medical Systems, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility, autoimmune diseases, oncology and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading respectively. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements, and contract development and manufacturing, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide.

Ypsomed has its headquarters in Burgdorf in Switzerland and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,100 employees.